Cancer is a global problem with 14.1 million new cases occurring annually and an expected increase of 68% by 2030. Ensuring effective and safe treatment remains a significant challenge for healthcare organisations. Studies have shown Proton Therapy (PT) to be effective in treating many types of tumours, including tumours of the prostate, brain, head and neck, central nervous system, lung, and gastrointestinal system as well as cancers that cannot be removed completely by surgery.
PT is the most advanced type of external-beam radiation therapy that uses protons at high energy to destroy cancer cells. It can be used alone or combined with other treatments e.g. radiation therapy, surgery, chemotherapy, and/or immunotherapy. PT is routinely used for cancer treatment, however it is limited by the sheer size and expense of the systems. There are currently only 102 operational PT facilities in the world, addressing less than 5% of clinical demand.
HIL has developed an ultra-compact, high-performance system for Proton Therapy. HIL’s advanced particle accelerator and beamline technologies make PT widely accessible by offering highly cost-effective single-room solutions. During this complimentary blended finance project, HIL intends to develop and manufacture its pre-Beta system in Israel's first PT centre. In addition, the development of the Beta version of the system will be carried out, which will enable the company to launch its first sales and undertake additional crucial commercial activities, preparing the company for widespread market penetration.
Fields of science
Call for proposal
See other projects for this call